Opyt vedeniya Moskovskogo registra bol'nykh akromegaliey: vozmozhnosti resheniya razlichnykh terapevticheskikh zadach


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The article presents the results of retrospective analysis of electronic medical records of 65 patients from Moscow registry of patients with acromegaly for 2011-2013, conducted to evaluate the efficacy of monotherapy with lanreotide and combination therapy with lanreotide and cabergoline in patients with acromegaly previously treated with octreotide. At the time of the last visit, a significant decrease in the insulin-like growth factor-1 (IGF-1) level in comparison with the data at the time of transfer was revealed; in 12 of the 50 initially decompensated patients, normalization of IGF-1 level was occurred. Decrease in the size of adenomas according to results of magnetic resonance imaging in the period after the transfer was observed in 12 patients, and normalization of biochemical parameters and a decrease in adenoma size were registered in 3 patients. In some patients, transfer from octreotide to lanreotide increased the long-term efficacy of treatment.

Толық мәтін

Рұқсат жабық

Авторлар туралы

M. Antsiferov

V. Pronin

Email: vspronin@yandex.ru

T. Alekseeva

L. Dorofeeva

Әдебиет тізімі

  1. Анциферов М.Б., Пронин В.С., Алексеева Т.М. Медикаментозное лечение пациентов с акромегалией, частично резистентных к терапии аналогами соматостатина // Фарматека 2011. № 16. С. 49-55.
  2. Дедов ИИ, Мельниченко Г.А. Акромегалия: патогенез, клиника, диагностика, дифференциальная диагностика, методы лечения. Пособие для врачей. М., 2012. 80 с.
  3. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004;151:317-24.
  4. Andries M, Glintborg D, Kvistborg A. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf) 2008;68(3):473-80.
  5. Attanasio R, Lanzi R, Losa M, et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 2008;14(7):846-55.
  6. Bevan JS, Newell-Price J, Wass JA, et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf) 2008;68(3):343-49.
  7. Caron P, Bevan J, Clermont A, Maisonobe P. Early and sustained tumour volume reduction and GH/IGF1 control in patients with GH-secreting pituitary macroadenoma primarily treated with lanreotide Autogel 120 mg for 48 weeks: the PRIMARYS study. The 15th European congress of Endocrinology, 2013.
  8. Caron P, Cogne M, Raingeard I, et al. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2006;64(2):209-14.
  9. Croxtall JD, Scott LJ. Lanreotide Autogel: a review of its use in the management of acromegaly. Drugs 2008;68(5):711-23.
  10. Ferone D, de Herder WW, Pivonello R, et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 2008;93(4): 1412-17.
  11. Florio T, Thellung S, Corsaro A, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf) 2003;59:115-28.
  12. Giustina A, Chanson P, Bronstein MD, et al. Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95(7):3141-48.
  13. Gutt B, Bidlingmaier M, Kretschmar K, et al. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes 2005;113(3):139-44.
  14. Hradec J, Krai J, Janota T, et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol 1999;83:1506-09.
  15. Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 update: executive summary. Endocr Pract 2011;17(4):636-46.
  16. Lombardi G, Colao., Marzullo P, et al. Multicenter Italian Study Group on Lanreotide. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 2002;25(11):971-76.
  17. Lucas T, Astorga R; Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf) 2006; 65(3):320-26.
  18. Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2012 Aug 18. [Epub ahead of print].
  19. Melmed S, Colao A, Barkan A, et al. Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009;94(5):1509-17.
  20. Melmed S, Cook D, Schopohl J, et al. Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010;13(1):18-28.
  21. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005;90(7):4405-10.
  22. Murray R, Melmed S. A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly.J Clinical Endocrinol Metab 2008; 93(8):2957-68.
  23. Roelfsema F, Biermasz NR, Pereira AM, Romijn JA. Therapeutic options in the management of acromegaly: focus on lanreotide Autogel. Biologics 200;2(3):463-79.
  24. Ronchi CL, Boschetti M, Degli Uberti EC, et al. Italian Multicenter Autogel Study Group in Acromegaly. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf) 2007;67(4):512-19.
  25. Schopohl J, Strasburger CJ, Caird D, et al. German Lanreotide Study Group. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes 2011;119(3):156-62.
  26. Sowinski J, Sawicka N, Piatek K, et al. Pharmacoeconomic aspects of the treatment of pituitary gland tumours. Contemp Oncol (Pozn) 2013;17(2):137-43.
  27. Tulipano G, Bonfanti C, Milani G, et al. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology 2001;73(5):344-51.
  28. Wasko R, Jankowska A, Kotwicka M, et al. Effects of treatment with somatostatin analogues on the occurrence of apoptosis in somatotropinomas. Neuro Endocrinol Lett 2003;24(5):334-38.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2013

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>